… ,11 and provided protection against severe malaria.Here, we report the initial results of
an ongoing phase 3 trial being conducted at 11 centers in 7 African countries (Fig. 1 in the …

… control group6 14 months after the first dose of vaccine administered in children 6 to 12 weeks
of … First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J …

… Herein, we report the final results from the same trial, including the efficacy of a booster
dose. … First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. …

… This analysis combines the first and second groups (referred to as the RTS,S/AS01 group)
and … >0 parasites/mm 3 ) was used for the evaluation of the impact of RTS,S/AS01 on clinical …

… Results from a previous phase 3 study showed efficacy of the … In the initial phase 3 study,
infants aged 6–12 weeks and children aged 5–17 months were randomly assigned (1:1:1) to …

… In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy … First results from large pilot
implementation in Africa show … from a phase 3 trial (NCT01148459) in children with WHO stage 1 …

… In a phase 3 randomized, controlled trials in children and young infants at 11 African sites
from March 27, 2009, through … First results of phase 3 trial of RTS,S/AS01 malaria vaccine in …

… African children aged 5–17 months and 6537 African infants aged 6–12 weeks at first vaccination,
… We assessed the effects of several covariates on anti-circumsporozoite antibody titres …

… children (age 5–17 months old at first vaccination) from the RTS,S/AS01 E phase 3 clinical
trial who received 3 … that this could have an impact on protective immunity to malaria [35]. Little …

… in infants and children in Africa: final results of a phase 3, … with RTS,S/AS01 E during the
first 3 years of the study, all of whom … recorded in the RTS,S/AS01 E phase 3 trial were chance …